OUR LEGACY
Chiesi USA was established in 2014 with the acquisition of Cornerstone Therapeutics Inc., as the culmination of a strong strategic alliance first formed in 2009. The organizations shared a focus on their people and a desire to address unmet medical needs in the specialty setting.
Evolution of Chiesi USA
-
October 2008
Cornerstone BioPharma Holdings merges with Critical Therapeutics and changes name to Cornerstone Therapeutics
-
May 2009
Announced ~$70M strategic alliance with Chiesi and gained U.S. marketing rights for Curosurf (poractant alfa)
-
July 2009
Announced agreement to acquire rights to Factive (gemifloxacin mesylate) from Oscient Pharmaceuticals
-
December 2011
Announced acquisition of Cardiokine Inc. and received WW rights to CRTX080
-
March 2012
Divested certain product rights for Factive and Spectracef (cefditoren pivoxil)
-
June 2012
Acquired EKR Therapeutics for approximately $150M
-
November 2012
Licensed U.S. marketing rights for Bethkis (Tobramycin Inhalation Solution) from Chiesi
-
May 2013
Licensed U.S. marketing rights for Pertzye (pancrelipase) from Digestive Care, Inc.
-
November 2013
Launch of CareDirect and Bethkis
-
February 2014
CRTX Stockholders Approve Merger with Chiesi
-
May 2014
Chiesi USA name change
-
December 2014
Acquired US rights for CHF 6384 (mannitol DPI)
-
June 2016
Acquired US Rights for Cleviprex (clevidipine), Kengreal (cangrelor) and Argatroban Injection from The Medicines Company
-
July 2017
FDA approved labeling revision for Pertzye (pancrelipase) to include gastrostomy tube administration for the contents of the 4,000 USP lipase units dosing strength
FDA approval of a 24,000 USP lipase units capsule of Pertzye
-
July 2018
Acquired US rights for PRX-102 from Protalix Biotherapeutics
-
December 2018
Chiesi USA becomes a Public Benefit Corporation under Delaware law
-
JANUARY 2019
Launch of RETAVASE® (reteplase)
-
FEBRUARY 2019
New Home Office opens in Cary, North Carolina
-
JUNE 2019
B-Corp certification
-
FEBRUARY 2020
Global Rare Disease Business Unit established with worldwide rights to FERRIPROX® (deferiprone)
-
NOVEMBER 2020
Chiesi acquires rights to REVCOVI® (elapegademase-lvlr)
-
MARCH 2021
Launch of BRONCHITOL® (mannitol)
-
FEBRUARY 2023
FDA Approves LAMZEDE® (velmanase alfa-tycv)
-
MARCH 2023
FDA approves FERRIPROX™ MR Deferiprone Extended-Release Tablets in Canada
-
MAY 2023
FDA approves ELFABRIO® (pegunigalsidase alfa-iwxj)
Pertzye rights returned to DCI
-
DECEMBER 2023
FDA approves FILSUVEZ® (birch triterpenes)
-
MAY 2024
Global Collaboration with Gossamer to develop and commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
CHIESI GROUP
The company was founded in Parma in 1935 when Giacomo Chiesi, a chemist who dreamed of doing research, bought the Laboratorio Farmaceutico Parmense and embarked on his entrepreneurial adventure. In the years that followed, sons Alberto and Paolo led an ambitious expansion and internationalization process that led to the development of a robust product portfolio and distribution in over seventy countries. Today Chiesi is still very much a family-led organization that embraces its entrepreneurial roots. The company continually strives to not only develop innovative solutions for its current customers, but is also exploring cutting-edge areas such as regenerative medicine and biotechnology. For a more detailed history of the Chiesi Group, click here.
PP-MULTI-0024 V44.0
